Enhanced Oral Bioavailability Through Nanoparticle- Based Solid Lipid Carrier: A Novel Approach To Drug Deliver

Reference

1. Gert Fricker, Torsten Kromp, Armin Wendel, Alfred Blume, Jürgen Zirkel, Herbert Rebmann, Constanze Setzer. "Phospholipids and Lipid-Based Formulations in Oral Drug Delivery." Pharmaceutical Research, 27(8), 1469-1486, 2010.
2. Charman W.N., 2000. Lipids, lipophilic drugs, and oral drug delivery-some emerging concepts. J. Pharm. Sci. 89:967-78
3. Mühlen A.Z., Schwarz C., Mehnert W., 1998. Solid lipid nanoparticles for controlled drug delivery-drug release and release mechanisms. Eur. J. Pharm. Biopharm. 45:149-55.
4. Faraji A.H., Wipf P., 2009. Nanoparticles in cellular drug delivery. Biorganics and medicinal chemistry. 17:29
5. Manjunath K., Venkateswarlu V., 2005. Pharmacokinetics, tissue distribution and bioavailability of clozapine solid lipid nanoparticles after intravenous and intraduodenal administration. J. Control Rel. 107:215-28.
6. Date A.A., Joshi M.D., Patravale V.B., 2007. Parasitic diseases: Liposomes and polymeric nanoparticles versus lipid nanoparticles. Adv. Drug Deliv. Rev. 59:505-21
7. Huynh N.T., Passirani C., Saulnier P., Benoit J.P., 2009. Lipid nanocapsules: A new platform for nanomedicine. Int. J. Pharm. doi:10.1016/j.ijpharm.2009.04.026
8. S. Pragati, S. Kuldeep, S. Ashok, M. Satheesh. "Solid Lipid Nanoparticles: A Promising Drug Delivery Technology." International Journal of Pharmaceutics and Nanotechnology, 2(2), 509-516, 2009.
9. Eliana B Souto, Joana F Fangueiro, Rainer H Müller , Solid lipid nanoparticles (SLN™) Fundamentals of pharmaceutical nanoscience, 91-116, 2013.
10. Müller R.H., Mader K., Gohla S., 2000. Solid lipid nanoparticles (SLN) for controlled drug delivery- a review of state of the art. Eur. J. Pharm. Biopharm. Versus drug nanocrystals. Int. J. Pharm. 317:82-9.50: 161-77.
11. Müller, R.H., Maaßen, S., Schwarz, C., Mehnert, W., 1997. Solid lipid nanoparticles (SLN) as potential carrier for human use: interaction with human granulocytes. J. Control Rel. 47:261-9
12. Müller R.H., Runge S., Mehnert W., Thünemann A.F., Souto E.B., 2006. Oral bioavailability of cyclosporine: Solid lipid nanoparticles (SLN)
13. Cavalli R., Caputo O., Carlotti M.E., Trotta M., Scarnecchia C., Gasco M.R., 1997. Sterilization and freeze drying of drug-free and drug-loaded solid lipid nanoparticles. Int. J. Pharm. 148: 47-54.
14. Narang A.S., Delmarre D., GAO D., 2007. Stable drug encapsulation in micelles and microemulsions. Int. J. Pharm. 345:9-25.
15. Joshi M.D., Müller R.H., 2009. Lipid nanoparticles for parenteral delivery of actives. Eur. J. Pharm. Biopharm. 71:161-72.
16. Kaur I.P., Bhandari R., Bhandari S., Kakkar V., 2008. Potential of solid lipid nanoparticles in brain targeting. J.Control Rel.127:97-109.
17. Chen Y., Dalwadi G., Benson H.A.E., 2004. Drug delivery across the blood brain barrier. Cur. Drug Deliv. 1:361-76.
18. Paliwal R., Rai S., Vaidya B., Khatri K., Goyal AK., Mishra N., Mehta A., Vyas S.P., 2009. Effect of lipid core material on characteristics of solid lipid nanoparticles designed for oral lymphatic delivery.Nanomedicine 5:184-91.
19. Piemi M.P.Y., Korner D., Benita S., Marty J.-P., 1999. Positively and negatively charged microemulsions for enhanced topical delivery of antifungal drugs. J.Control Rel. 58(2): 177-87.
20. Morel S., Ugazio E., Cavalli R., Gasco M.R., 1996. Thymopentin in solid  lipid nanoparticles. Int. J. Pharm.132:259-61.
21. Patrícia Severino, Tatiana Andreani, Ana Sofia Macedo, Joana F Fangueiro, Maria Helena A Santana, Amélia M Silva, Eliana B Souto Current state?of?art and new trends on lipid nanoparticles (SLN and NLC) for oral drug delivery Journal of drug delivery 2012 (1), 750891, 2012.
22. Huang G., Zhang N., Bi X., Dou M., 2008. Solid lipid nanoparticles of temozolomide: Potential reduction of cardiac and nephric toxicity. Int. J. Pharm.355:314-20.
23. Porter C.J.H., Charman W.N., 2001. In vitro assessment of oral lipid based formulations. Adv. Drug Deliv. Rev. 50:127-47.
24. Radomska-Soukharev A., 2007. Stability of lipid excipients in solid lipid nanoparticles. Adv. Drug Deliv. Rev. (59):411-8.
25. Freitas C., Müller R.H., 1998. Effects of light and temperature on zeta potential and  physical stability in solid lipid nanoparticles (SLN) dispersions. Int. J. Pharm. 168:221-9.
26. Shaji J., Joshi V., 2005. Self-microemulsifying Drug Delivery Systems (SMEDDS) for improving oral bioavailability of hydrophobic drugs and its potential to give sustain release dosage forms. Indian J. Pharm. Educ. 39(3):130-135.
27. Suresh G., Manjunath K., Venkateswarlu B., Satyanarayana V., 2007. Preparation, characterization, and in vitro and in vivo evaluation of Lovastatin solid lipid nanoparticles. AAPS PharmSciTech 8 (1): Article 24.
28. Rahul Nair, K. Vishnu Priya, K.S. Arun Kumar, T. Md Badivaddin, M. Sevukarajan. "Formulation and Evaluation of Solid Lipid Nanoparticles of Water-Soluble Drug:   Isoniazid." Journal of Pharmaceutical Sciences and Research, 3(5), 1256, 2011.
29. Porter, C.J.H., Charman, and W.N. "Intestinal Drug Transport: An Update." Advanced Drug Delivery Reviews, 50:61-80, 2001.
30. Porter C.J.H., Pouton C.W., Cuine C.F., Charman W., 2008. Enhancing intestinal drug solubilization using lipid-based delivery system. Adv. Drug Deliv. Rev. 60:673-91.
31. Hussain N., Jaitley V., Florence A.T., 2001. Recent advances in the understanding of uptake of microparticulates across the gastrointestinal lymphatics. Adv. Drug Deliv. Rev.50 (1-2):107-42.
32. Korsmeyer R.W., Gurny R., Doelker E., Buri P., Peppas N.A., 1983. Mechanisms of solute release from porous hydrophilic polymers. Int. J. Pharm., 15: 25-35.
33. Luo Y.F., Chen D.W., Ren L.X., Zhao X.L.,Qin J., 2006. Solid lipid nanoparticles for enhancing vinpocetine's oral bioavailability. J. Control Rel.114:54-9.
34. Li H., Zhao X., Ma Y., Zhai G., Li L., Lou H.,2009. Enhancement of gastrointestinal absorption of quercetin by solid lipid nanoparticles. J. Control Rel. 133:238-44.
35. Doijad R.C., Manvi F.V., Godhwani D.M., Joseph R., Deshmukh N.V., 1998. Formulation and targeting efficiency of cisplatin engineered solid lipid nanoparticles. Indian J. Pharm. Sci. 70(2):203-7.
36. Florence, A.T. "Nanoparticle Uptake by Oral Route: Fulfilling Its Potential?" Drug Discovery Today: Technologies, 2(1), 75-81, 2005
37. Sanjay Singh, Subhashis Chakraborty, Dali Shukla, Brahmeshwar Mishra. "Lipid–An Emerging Platform for Oral Delivery of Drugs with Poor Bioavailability." European Journal of Pharmaceutics and Biopharmaceutics, 73(1), 1-15, 2009
38. Venkateswarlu V, Manjunath K., 2004. Preparation, characterization and in vitro release kinetics of clozapine solid lipid nanoparticles. J. Control Rel. 95:627-38.
39. Yuan H., Chen J., Du. Y.-Z., Hu F.-Q., Zeng S., Zhao H.-L., 2007. Studies on oral absorption of stearic acid SLN by novel fluorometric method. Col. Surf. B 58:157-64.
40. Huang G., Zhang N., Bi X., Dou M., 2008. Solid lipid nanoparticles of temozolomide: Potential reduction of cardiac and nephric toxicity. Int. J. Pharm.355:314-20.
41. Mehnert, W., Mäder, K. "Solid Lipid Nanoparticles: Production, Characterization, and Applications." Advanced Drug Delivery Reviews, 47:165-196, 2001.
42. Mukherjee, S., Ray, S., Thakur, R.S. "Solid Lipid Nanoparticles: A Modern Formulation Approach in Drug Delivery Systems." Indian Journal of Pharmaceutical Sciences, 71:349-358, 2009.
43. Wissing, S.A., Kayser, O., Müller, R.H. "Solid Lipid Nanoparticles for Parenteral Drug Delivery." Advanced Drug Delivery Reviews, 56:1257-1272, 2004.
44. Cortesi, R., Esposito, E., Luca, G., Nastruzzi, C. "Production of Lipospheres as Carriers for Bioactive Compounds." Biomaterials, 23, 2283-2294, 2002.
45. Costa P., Lobo J.M.S., 2001. Modeling and comparison of dissolution profiles.Eur. J. Pharm. Sci. 13:123-33.
46. Olbrich C., Kayser O., Müller R.H., 2002a. Enzymatic degradation of Dynasan 114 SLN- effect of surfactants and particle size. J. Nanoparticle Res.4:121-29.
47. Olbrich C., Kayser O., Müller R.H., 2002b. Lipase degradation of Dynasan 114 and 116 solid lipid nanoparticles (SLN)-effects of surfactants, storage time and crystallinity. Int. J. Pharm. 237:119-28.
48. Olbrich C., Müller R.H., 1999. Enzymatic degradation of SLN-effect of surfactant and surfactant mixtures. Int. J. Pharm. 180:31-39.
49. Rudolph C., Schillinger U., Ortiz A., Tabatt K., Plank C., Müller R.H., 2004. Application of novel solid lipid nanoparticles (SLN)-gene vector formulations based on a diametric HIV-1 VAT-peptide in vitro and in vivo. Pharmaceutics. Res. 21:1662-9.
50. Date A.A., Joshi M.D., Patravale V.B., 2007. Parasitic diseases: Liposomes and polymeric nanoparticles versus lipid nanoparticles. Adv. Drug Deliv. Rev. 59:505-21.